PATENT ABSTRACTS 379

but is not biologically active upon transfection Improved vectors and methods for expressing into a wild type (i.e., ung + ) E. coli host cell. Ex- cloned genes of prokaryotic or eukaryotic origin pression of a desired change, present in the newly and methods of making such vectors are dis- synthesized non-uracil-containing covalently closed, the improved vectors comprising pro- closed circular complementary strand, is thus rooters and operators from lambda phages and favored. The procedure has been applied to preferably do not include an active cro gene or an mutations introduced via both ob- active N gene, the vectors having at least one ligonucleotides and error-prone polymerization, endonuclease recognition site for cloning desired The inclusion of two additional simple treatment genes less than about 300 base pairs from the steps before transfection results in a site-specific promoters and operators and being useful, as are mutation frequency approaching 100%. methods utilizing the vectors, in producing a

wide variety of prokaryotic, eukaryotic and viral polypeptides, hormones, enzymes, antigens,

4873196 proteins and amino acids.

P R O T O P L A S T S O F T E M P E R A T U R E - S E N S I T I V E 4874703 S T R A I N S O F N E U R O S P O R A

C R A S S A O S - 1 E X P R E S S I O N V E C T O R S F O R U S E IN E. C O L I

Claude Selitrennikoff assigned to University Pa- tents Inc S Richard Jaskunas assigned to Eli Lilly and

Company This invention concerns conditional protoplasts of temperature-sensitive variants of the osmotic- The present invention provides a transcriptional 1 mutant strain of Neurospora crassa, and and translational activating sequence derived method of making same. from the lambda pL transcriptional activating

sequence and the E. coli lpp translational ac- tivating sequence. The activating sequence has

4874698 been cloned into recombinant DNA expression vectors into which DNA sequences encoding

P R O C E S S F O R P R O D U C I N G funtional polypeptides can be readily inserted T R Y P T O P H A N and expressed. The activating sequence of the

present invention has been shown to drive high- Akio Ozaki, Ryoich Katsumata, Tetsuo Oka, level expression of a bovine growth hormone Tokyo, Japan assigned to Kyowa Hakko Kogyo derivative and a human growth hormone deriva- Co Ltd rive in E. coli. Preferred expression vectors of the

present invention also comprise the ci857 Disclosed is a process for producing tryptophan temperature-sensitive lambda pL repressor gene, by transforming a host microorganism a rop- derivative of the plasmid pBR322 belonging to the genus Corynebacterium or replicon, and a tetracycline resistance-conferring Brevibacterium with a recombinant DNA of a gene. DNA fragment containing a gene involved in the biosynthesis of tryptophan and a vector DNA, culturing the transformant in a nutrient medium, 4874705 accumulating tryptophan in the culture medium and recovering tryptophan therefrom. D N A E N C O D I N G A N A N T I G E N I C

P R O T E I N D E R I V E D F R O M E I M E R I A T E N E L L A A N D

4874702 V A C C I N E S F O R P R E V E N T I O N O F C O C C I D I O S I S C A U S E D BY

V E C T O R S A N D M E T H O D S F O R E I M E R I A T E N E L L A M A K I N G S U C H V E C T O R S A N D

F O R E X P R E S S I V E C L O N E D William Andrews, Virginia M Brothers, James G G E N E S Files, Iren Kuhn, Michael McCaman, Leland

Paul, Stacey Sias, Thomas Gore, Kare lZ New- Walter C Fiefs, Rene Erik Remaut, Destelber- man, John L Tedesco assigned to Solvay & Cie S gen, Belgium assigned to Biogen Inc A

as~; PATENT ABSTRACTS

A genomic DNA molecule having the nucleic products. The DNA sequences and recombinant acid sequence set forth in FIG. 1 and encoding DNA molecules are characterized in that they an antigenic protein derived from Eimeria code on expression for a human phospholipase tenella has been isolated. The protein has a inhibitor-like polypeptide. In appropriate hosts molecular weight of about 25,000 daltons and is these DNA sequences permit the production of composed of two polypeptides joined by a dis- human phospholipase inhibitor-like poly- ulfide bond. One of the polypeptides is charac- peptides useful as anti-inflammatory agents and terized by a molecular weight of about 17,000 methods in the treatment of arthritic, allergic, daltons and by a blocked N-terminal amino acid dermatologic, ophthalmic and collagen diseases and having the amino acid sequence set forth in as well as other disorders involving in- FIG. 1. The other polypeptide is characterized flammatory processes. by a molecular weight of about 8,000 daltons and has the amino acid sequence set forth in FIG. 1. A cDNA molecule encoding the 25,000 4874748 dalton polypeptide with a continuous amino acid sequence has been inserted into expression vectors capable of expressing the 25,000 dalton C L O N I N G V E C T O R S F O R polypeptide directly or as a fused polypeptide. S T R E P T O M Y C E S A N D U S E The polypeptides produced are used in vaccines T H E R E O F I N M A C R O L I D E to immunize chickens against infection by A N T I B I O T I C P R O D U C T I O N Eimeria tenella.

Leonard Katz, James Tuan, James B McAlpine assigned to Abbott Laboratories

4874706 DNA cloning shuttle vectors, including a cosmid

M A N U F A C T U R E A N D U S E O F shuttle vector, for E. coli and Streptomyces are T A G E T I T O X I N disclosed. Specifically, disclosed shuttle vectors

pAL7002 (NRRL B-18055) and pNJl (NRRL B- 18054) contain an E. coli origin of replication,

Richard D Durbin, Jean H Lukens, Thomas F Streptomyces replication functions, and anti- Uchytil, Nichola Rhodehamel assigned to biotic resistance markers for both E. coli and Wisconsin Alumni Research Foundation Streptomyces. In addition, pNJ1 contains a cos

sequence. Novel 2-norerythromycin antibiotics An exotoxin of the plant pathogen, Pseudo- A, B, C, and D, which were produced in a strain monas syringae pv. tagetis selectively inhibits the Streptomyccs erythreus 12693-240 (NRRL B- development of chloroplasts in growing plant 18053) transformed by pNJl bearing DNA from tissue. The exotoxin, known as tagetitoxin, can Streptomyces antibioticus, are also disclosed. be produced efficiently from a mutant high- The present invention also provides a method for producing line of the bacteria, designated producing novel antibiotics. This method for C42mr2+. The tagetitoxin can also be readily antibiotic production is applied to the trans- purified from the culture medium of the bacteria, formation of a blocked mutant of S. erythreus

with genomic DNA from S. antibioticus but may be more broadly applied to genes to antibiotic-

4874743 producing strains transformed into cells which are blocked in the pathway for production of a

D N A S E Q U E N C E S , different antibiotic. R E C O M B I N A N T D N A

M O L E C U L E S A N D P R O C E S S E S F O R P R O D U C I N G H U M A N 4874845

P H O S P H O L I P A S E I N H I B I T O R - L I K E P O L Y P E P T I D E S T L Y M P H O C Y T E R E C E P T O R

S U B U N I T Barbara P Wallner, R Blake Pepinsky, Jeffrey L Garwin assigned to Biogen Inc Haruo Saito, David M Kranz, Herman N Eisen,

Susumu Tonegawa assigned to Massachusetts DNA sequences, recombinant DNA molecules Institute of Technology and hosts transformed with them which produce human phospholipase inhibitor-like poly- Disclosed is a heterodimeric T lymphocytes peptides andmethods of making and using these receptor subunit. The subunit consists of